Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Bristol Myers Squibb

BMY Healthcare Unknown Updated August 01, 2026
$65.30
52W $42.52 – $65.66
56/100
$133.37B
14.4
0.23
AI Committee Verdict
Watch
Conviction: Contested · 43% agreement · 7 analysts
+1.4%
-3.2%
0.45:1
Contested

Is BMY Bullish or Bearish?

Mixed. Innellis AI committee rates Bristol Myers Squibb (BMY) Watch with a composite score of 56/100 , based on 7 analysts with 43% agreement. Last updated August 01, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +3.83 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -16.17 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 26.3% yoy. Risk Analyst remains cautious — high leverage (debt-to-equity 2.44) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • ROE of 41.6% shows genuine earnings power backing the valuation — Value
  • Dividend yield of 3.9% pays you to wait — Value
  • EPS growing 26.3% YoY — Growth
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
Bear Case
  • Price-to-book of 5.9x prices in significant intangible value — Value
  • Debt-to-equity of 2.44 adds balance-sheet risk to the value case — Value
  • RSI at 80 is in overbought territory — Technical
  • Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
  • High leverage (debt-to-equity 2.44) amplifies downside in a stress scenario — Risk
  • Bollinger bandwidth of 17.2% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 01, 2026
Overall Committee Score
56/100
Agreement
43%
Analysts
7
Conviction
Contested
Sector Rank
Top 59%
of 93 Healthcare peers
Value Analyst neutral
50 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 41.6% shows genuine earnings power backing the valuation
− Price-to-book of 5.9x prices in significant intangible value
Growth Analyst bullish
72 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 26.3% YoY
Technical Analyst neutral
57 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 80 is in overbought territory
Risk Analyst bearish
32 / 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 2.44) amplifies downside in a stress scenario
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
66 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 107 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2535.03)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 57.9 to 56.2.

Analyst-level changes:
  • Growth Analyst: score 82->72 (-10); +1 bullish signal(s).
  • Macro Analyst: stance neutral->bullish; score 58->70 (+12).
  • News Analyst: score 70->66 (-4); +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Risk Analyst: +2 bearish signal(s).
  • Technical Analyst: +1 bearish signal(s).
  • Value Analyst joined: neutral at 50.

Comparing 2026-07-31 to 2026-08-01 (1 day apart).

Technical Analysis

RSI (14)
79.6
Overbought
MACD Histogram
0.480
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Lh Ll
Support
$63.22
Resistance
$66.22
Bollinger %B
0.97
Inside Bands
Price vs Moving Averages
EMA 9
$62.98 Above
EMA 21
$60.98 Above
EMA 50
$59.18 Above
EMA 200
$56.22 Above

Fundamental Analysis

Valuation
77
Growth
87
Profitability
1
Financial Health
45
Cash Flow
37
Valuation
P/E Ratio 14.4×
P/B Ratio 5.98×
PEG Ratio 0.17
Dividend Yield 0.04%
52W High $65.66
52W Low $42.52
Quality & Growth
ROE 38.2%
ROA 7.8%
Gross Margin 70.2%
Operating Margin 28.3%
Revenue Growth YoY
Debt / Equity 1.93
AI Fundamental Assessment
P/E ratio of 14.4 (inexpensive relative to a 15-40x range); Price-to-book of 6.0x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.4%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.7%; Current ratio of 1.53 (healthy short-term liquidity); Debt-to-equity of 1.93; Free cash flow margin of 0.9% (thin cash generation); Free cash flow per share is positive (6.02); Most recent quarter beat estimates by 27.2%; 5 consecutive earnings beats; EPS growth accelerating (+25.4% -> +29.1% QoQ); Average YoY EPS growth of 39.7%; Analyst estimates rising over recent quarters
Get the Full BMY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore BMY Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime